What are the recommended neostigmine dosing regimens for reversal of non‑depolarising neuromuscular blockade, postoperative ileus, and acute myasthenia gravis exacerbations?

Neostigmine Dosing

For reversal of non-depolarizing neuromuscular blockade, administer neostigmine 0.04 mg/kg (40 mcg/kg) intravenously when four responses to train-of-four (TOF) stimulation are present, always with concurrent atropine 0.02 mg/kg or glycopyrrolate. 1, 2

Reversal of Neuromuscular Blockade

The 2020 Anaesthesia guidelines provide a clear algorithmic approach based on TOF monitoring 1:

Decision Algorithm:

If TOF responses < 4:

• Wait and maintain anesthesia
• Reassess TOF later
• Do NOT administer neostigmine yet

If TOF responses = 4:

• Administer neostigmine 0.04 mg/kg IV
• Co-administer atropine 0.02 mg/kg
• Expect efficacy (TOF ratio ≥ 0.9) in 10-20 minutes

Dose Adjustments Based on Blockade Depth:

For very shallow blockade (TOF ratio 0.5-0.6):

• Reduce neostigmine dose by half to 0.02 mg/kg (20 mcg/kg) 1
• This achieves TOF ratio 1.0 in approximately 6 minutes 1

For moderate blockade (TOF ratio 0.4):

• Use 0.025-0.03 mg/kg (25-30 mcg/kg) 1
• Recovery to TOF ratio 1.0 occurs in 6-11 minutes

Standard dose for TOF count of 4:

• 0.04 mg/kg remains the recommended dose 1, 2
• For TOF count of 2-3, may use up to 0.05 mg/kg 3

Critical Caveats:

Maximum dosing: Never exceed 0.07 mg/kg or 5 mg total, whichever is less 2. The FDA label explicitly states this ceiling dose applies to all patients including pediatrics.

Avoid excessive dosing: Administering neostigmine 40 mcg/kg when TOF ratio is already > 0.9 can paradoxically impair neuromuscular transmission and induce TOF fade lasting 17-52 minutes 1. This is a critical pitfall—if blockade has spontaneously reversed, neostigmine can worsen function.

Mandatory monitoring: Continue quantitative TOF monitoring after neostigmine administration until TOF ratio ≥ 0.9 is confirmed 1. Recovery time ranges 10-30 minutes depending on blockade depth 1.

Timing considerations: If only 0-1 TOF responses present, neostigmine will not effectively reverse blockade—wait for at least 2 responses before administering 3.

Pediatric Dosing:

Use the same weight-based dosing as adults (0.03-0.07 mg/kg) 2. However, infants and children have greater risk from incomplete reversal due to decreased respiratory reserve, so err toward higher doses (up to 0.07 mg/kg) rather than lower 2. Always administer anticholinergic first in pediatrics to prevent bradycardia and hypotension, as their blood pressure is particularly sensitive to heart rate changes 2.

Special Populations:

Elderly patients: No dose adjustment needed, but monitor for longer duration as neostigmine elimination is prolonged 2. Spontaneous recovery is also slower in elderly, so extended monitoring is essential.

Renal impairment: No dose adjustment required, but elimination half-life is prolonged in anephric patients 2. Monitor longer to ensure neuromuscular blocking agent effects don't outlast neostigmine, especially if using renally-cleared NMBAs.

Hepatic impairment: No dose adjustment appears necessary 2. However, if hepatically-cleared NMBAs were used, their prolonged duration may outlast neostigmine's effect.

Postoperative Ileus

For acute colonic pseudo-obstruction or severe postoperative ileus, administer neostigmine 2 mg IV as a single bolus dose. 4

• Onset of action: 4-30 minutes (median) 4
• Expect prompt evacuation of flatus or stool with reduction in abdominal distention
• Most frequent side effect is abdominal cramping 4
• Bradycardia is infrequent and rarely requires atropine 4
• Both bolus and infusion are effective 4

Important consideration: Recent evidence suggests neostigmine/glycopyrrolate for neuromuscular reversal may actually delay gastrointestinal recovery compared to sugammadex, with longer time to first stool (3 vs 2 days) 5. This is mediated through effects on the cholinergic anti-inflammatory pathway.

Myasthenia Gravis

The evidence provided does not contain specific neostigmine dosing protocols for acute myasthenic exacerbations. The available research discusses intranasal neostigmine as effective in 5-15 minutes for generalized MG 6, and newer guidelines emphasize acetylcholinesterase inhibitors as part of treatment 7, 8, but precise IV dosing for crisis management is not detailed in these sources.

For myasthenia gravis management, the focus has shifted toward immunotherapies, monoclonal antibodies, and complement inhibitors 7, 8, with acetylcholinesterase inhibitors playing a supportive rather than primary role in acute exacerbations.